Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
about
Pericytes, an overlooked player in vascular pathobiologyDiabetic Macular Edema Pathophysiology: Vasogenic versus InflammatoryUpdate on corticosteroids for diabetic macular edemaDiabetic macular oedema: evidence-based treatment recommendations for Asian countries.Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesAnti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept.Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.Evidence-Based Treatment of Diabetic Macular Edema.Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review.Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion.Changes in Retinal Nerve Fiber Layer Thickness after Multiple Injections of Novel VEGF Decoy Receptor Conbercept for Various Retinal Diseases.Diabetic Retinopathy: Battling the Global Epidemic.Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNVA Quantitative Approach to Predict Differential Effects of Anti-VEGF Treatment on Diffuse and Focal Leakage in Patients with Diabetic Macular Edema: A Pilot StudyBaseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007-2015.Evaluation of Diabetic Retinal Screening and Factors for Ophthalmology Referral in a Telemedicine Network.Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option.Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy.Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society).Diabetic retinopathy: current understanding, mechanisms, and treatment strategiesComparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema.Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels.Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema.Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases.Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumabA longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.Recent advances in the management and understanding of diabetic retinopathy.
P2860
Q28070053-05D23E8A-AD6B-46A3-8D75-05BA6906DE4BQ28070894-2B09EA51-7E4E-4B8E-B0CC-218F7FEBF97CQ28074846-D236C8D0-56D9-4E61-B184-144146F7B277Q30101045-F94437A4-481C-4047-BA7A-0137ED662CF6Q30244247-F18D19C3-EA98-4D75-BE04-AD512EBC2B1CQ30490738-2AC61DBC-7D8A-4D38-ABC2-32F5BF1F59C8Q31163540-FC85A188-413A-47D3-BE23-D8DA5F47C441Q33740152-EEC3D9F4-EF68-4B39-94E6-39F1E74E9B4CQ33840787-5608FEF2-1C72-4A4E-AA02-949FCBC3280AQ34558187-2FAFFE44-FA46-4A7F-B14A-C4523FA7972EQ35954145-A0BECF46-29E1-4820-80ED-CE2244B62291Q35984696-24EA5B7D-6116-4D42-8A5D-CD80C07B8056Q36155647-06A3D514-8DAC-44D1-8528-98D85D7E39D4Q36242390-9089D27C-45EB-43AA-98BE-D184FE0E0A9AQ36297613-4D7802B9-75F2-4933-A112-296A2D2A533EQ36324841-DBCB4EB6-EE79-4E60-B076-F1E096DCC9B7Q36338786-22AEA8C9-51CE-46BD-9610-740AB09E8AA8Q36407311-6278ED38-1862-4DBD-A193-10586177C949Q37288622-3F631138-1A32-4B5B-AFA8-CCBFB530C165Q37476086-06FF2E1B-6FA5-4DB2-8D92-46848413EDB0Q37494858-091A5041-48B4-4791-B084-D2DB275F6B52Q37683627-4076FD6D-235C-4EA6-AD8B-BE8B53C969CFQ37731896-32D3A82F-256D-4FE3-9E4B-A53E44DAC52FQ38376975-1D27189B-07C9-4297-AF1D-9CC830DFEF6FQ38673270-3DA9AE1D-906C-4A3C-BFC0-0787206CEA88Q38777076-80AF49CF-FE4F-4F52-8301-93C8A445802EQ38792697-545A8C12-82CB-44D7-B0E0-0D9F8D9E5001Q38817006-47D1646F-81F9-423F-B45F-6D191949F30EQ38937864-A62C0AA0-0B56-4F7F-BA74-AFE06171E7ADQ39203881-D009D53B-06E2-49DB-AB27-6D59927E839FQ39292954-CFB213BE-4C54-48E8-A856-CE766C06327CQ39427264-59655A58-4C08-4AA4-A1CC-7EB3CFB8F0A1Q39445950-ADE8E7D8-48CB-4664-A1CD-80435FF04BBCQ41025677-7F9EE6F6-42B9-4288-BAD5-B227DA78E692Q41181429-9565AAE1-82C1-4068-AC20-B2788954F9FEQ41341809-63EBEB08-7417-4398-8DC4-942CA21A691FQ41572871-1576D153-7D58-4F0D-A80D-C0B92F02A177Q42361471-F2AC411E-7A6F-4F45-AF69-82DD74774063Q45648693-B94A2B80-2534-4D3E-99AD-1FCB78A9BDC0Q47168388-A861D3AC-6F06-4DA6-A160-E69913D0EAE8
P2860
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@ast
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@de
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@en
type
label
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@ast
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@de
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@en
prefLabel
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@ast
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@de
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@en
P2093
P2860
P1433
P1476
Aflibercept, Bevacizumab, or R ...... ess Randomized Clinical Trial.
@en
P2093
Adam R Glassman
Alexander J Brucker
Allison R Ayala
Chirag Jhaveri
Diabetic Retinopathy Clinical Research Network
Frederick L Ferris
G Robert Hampton
John A Wells
Lee M Jampol
Michele Melia
P2860
P304
P356
10.1016/J.OPHTHA.2016.02.022
P407
P577
2016-02-25T00:00:00Z